A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
Patients discharged alive after traumatic injury had a 9-fold higher risk of suicide than the general population 2 years after hospitalization, according to cohort study findings.
Patients discharged alive after traumatic injury had a 9-fold higher risk of suicide than the general population 2 years after hospitalization, according to cohort study findings.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A multicenter randomized clinical trial found that adding omega-3 fatty acid supplements to psychotherapy did not improve outcomes in children and adolescents with moderate-to-severe major depression.
A multicenter randomized clinical trial found that adding omega-3 fatty acid supplements to psychotherapy did not improve outcomes in children and adolescents with moderate-to-severe major depression.
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
A large network meta-analysis found specific noninvasive brain stimulation (NIBS) modalities improved symptoms in treatment-resistant schizophrenia (TRS).
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this insightful discussion, Psych Congress Faculty Member Timothy Wilens, MD, dissects the challenges clinicians may face when diagnosing and treating common psychiatric comorbidities in individuals with ADHD.
In this insightful discussion, Psych Congress Faculty Member Timothy Wilens, MD, dissects the challenges clinicians may face when diagnosing and treating common psychiatric comorbidities in individuals with ADHD.
The Clinical Education section of NP Psych Navigator brings together a range of tools to help you stay informed. Access article summaries, review an interactive case study, test your knowledge with quizzes, and discover upcoming educational events—curated with psychiatric nurse practitioners in mind. Explore!
ABBV-US-02294-MC, V1.0 | 12/2025 | AbbVie Medical Affairs
Psych Navigator brings together psychiatry content, including clinical insights and educational tools, to help support your professional development. Explore current topics and updates across major depressive disorder, bipolar I disorder, and schizophrenia today!
ABBV-US-02302-MC, V1.0 | 12/2025 | AbbVie Medical Affairs
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
Julie Carbray, PhD, PMHNP-BC, APRN, discusses how emerging therapies for bipolar disorder differ from traditional mood stabilizers, including improved tolerability and reduced side effects.
Julie Carbray, PhD, PMHNP-BC, APRN, discusses how emerging therapies for bipolar disorder differ from traditional mood stabilizers, including improved tolerability and reduced side effects.
In PTSD, brexpiprazole in combination with sertraline was associated with greater improvements in symptom severity and functioning compared to sertraline in combination with placebo across symptom clusters.
In PTSD, brexpiprazole in combination with sertraline was associated with greater improvements in symptom severity and functioning compared to sertraline in combination with placebo across symptom clusters.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
They are back! Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in...
They are back! Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.